What changed from existing technology?
This study shows that some breast cancer cells are less sensitive to radiation because they have high levels of a process called autophagy and a protein called p62, which might help them survive treatment.
This study identifies a new mechanism where the combination of increased autophagy and p62 levels contributes to resistance against radiation in breast cancer cells.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
iotherapy with eventual attainment of radioresistance remains a major challenge for this oncologic treatment modality. To overcome this limitation, it is
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding could help in developing strategies to overcome radioresistance in triple-negative breast cancer by targeting autophagy and p62 pathways.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.